Biogen commits up to $200m in Proteostasis pact
This article was originally published in Scrip
Executive Summary
Proteostasis Therapeutics may earn up to $200m in upfront and milestone payments plus royalties under a collaboration with Biogen Idec for the development of therapeutics that inhibit Usp14.